SUBSCRIBE
SUBSCRIBE
News   Deals

Hapoalim Securities Expects Eli Lilly and Company To Acquire Amylin Pharmaceuticals, Inc. Post Approval Of AMLN’s Bydureon

June 28, 2010 | 
1 min read
Benzinga.com -- Analyst Jon LeCroy of Hapoalim Securities reiterates his "buy" rating on Amylin Pharmaceuticals (NASDAQ: AMLN). The target price for AMLN is set to $22.
Mergers & acquisitions
Eli Lilly and Company
MORE ON THIS TOPIC
Big fish eats small, takeover of the company. Art collage.
Mergers & acquisitions
BioNTech Swallows Vaccine Rival CureVac in $1.25B All-Stock Acquisition
June 12, 2025
 · 
3 min read
 · 
Tristan Manalac
Pictured: Bristol Myers Squibb office in California
Deals
BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem
June 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Crowdfunding concept with money icon and human hands in retro 80s collage mixed media vector illustration. Idea for financing business project, funding, philanthropy, cooperation, bank credit and startup development.
Weight loss
Lilly Bites Again in $650M Muscle-Preserving Treatment Pact With Juvena
June 11, 2025
 · 
1 min read
 · 
Annalee Armstrong
Podcast
RFK Axes CDC Vaccine Advisors; Metsera’s Weight Loss Win; FDA Supports CGT
June 11, 2025
 · 
1 min read
 · 
Heather McKenzie